7
3M
6
4
0.14
1
- Areas of investment
Summary
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Walloon, startups are often financed by Takeda Ventures, Spinventure, Jean-Pierre Delwart. The meaningful sponsors for the fund in investment in the same round are Spinventure, Meusinvest, Eurostars. In the next rounds fund is usually obtained by Rodolphe de Spoelberch, Korea Investment Partners, Inventures SA.
The fund is generally included in less than 2 deals every year. Deals in the range of 5 - 10 millions dollars are the general things for fund. The top activity for fund was in 2018.
Among the most popular portfolio startups of the fund, we may highlight Convert Pharmaceuticals, Univercells. Among the most popular fund investment industries, there are Therapeutics, Health Care. The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
Investments analytics
Analytics
- Total investments
- 7
- Lead investments
- 4
- Exits
- 1
- Follow on index
- 0.14
- Investments by industry
- Biotechnology (6)
- Health Care (3)
- Pharmaceutical (2)
- Manufacturing (2)
- Business Development (1) Show 2 more
- Investments by region
-
- Belgium (5)
- United States (2)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 0.29
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Convert Pharmaceuticals | 28 Feb 2018 | Biotechnology, Pharmaceutical, Business Development | Early Stage Venture | 16M | Liège, Liège, Belgium |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.